Loading
A phase 1/2 trial of BVAC-E6E7 (low level) in head and neck squamous cell carcinoma, run by Cellid Co., Ltd., now recruiting.
A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC. is a phase 1/2 interventional study registered as NCT06797986 by Cellid Co., Ltd., with 37 participants planned, started 2026-02-04 and due to reach its primary completion in 2027-03. Interventions recorded: BVAC-E6E7 (low level), BVAC-E6E7 (high level) and BVAC-E6E7 (RP2D).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares HPV-positive oropharyngeal cancer, Head and neck squamous cell carcinoma and the tag pipeline.
Shares HPV-positive oropharyngeal cancer, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares HPV-positive oropharyngeal cancer, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/